Literature DB >> 10706463

Human herpesvirus 8 and Epstein Barr-virus in a cutaneous B-cell lymphoma and a malignant cell line established from the blood of an AIDS patient.

P Morand1, M Buisson, H Collandre, B Chanzy, O Genoulaz, M J Bourgeat, N Pinel, P Leclercq, D Leroux, V Marechal, L Fritsch, R Ruigrok, J M Seigneurin.   

Abstract

Human Herpesvirus 8 (HHV-8) has been consistently associated with Primary Effusion Lymphoma (PEL or body-cavity-based lymphoma) but not with other lymphomas. This paper reports on an AIDS patient without obvious malignant effusion in body cavities but with a cutaneous lymphoma where HHV-8 and Epstein-Barr virus (EBV) were detected by PCR and electron microscopy. Both viruses were also detected in all the cells of a malignant cell line (BBG1) established from the patient's peripheral blood mononuclear cells. As in PEL and PEL-derived cell lines, both the tumor and the lines lacked B-antigen expression in immunological studies but were of the same B origin as shown by clonal immunoglobulin gene rearrangements. In contrast to other co-infected cell lines, BBG1 and subclones spontaneously expressed the HHV-8 lytic antigens p40, p27, p60 and the EBV transforming latent antigen EBNA2. These data suggest that the clinical and biological features of HHV-8-and EBV-associated lymphomas could be wider than has been described to date in PEL particularly with the in vivo presence of circulating malignant dually-infected cells engaged in a spontaneous HHV-8 lytic infection.

Entities:  

Mesh:

Year:  1999        PMID: 10706463     DOI: 10.3109/10428199909145743

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

1.  Quantitative analysis of human herpesvirus 8 viral load using a real-time PCR assay.

Authors:  F Lallemand; N Desire; W Rozenbaum; J C Nicolas; V Marechal
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

2.  KSHV/HHV-8 associated lymph node based lymphomas in HIV seronegative subjects. Report of two cases with anaplastic large cell morphology and plasmablastic immunophenotype.

Authors:  A Carbone; A Gloghini; E Vaccher; G Marchetti; G Gaidano; U Tirelli
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

Review 3.  Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man: A Case Report and Review of the Literature.

Authors:  William R Foster; Alina Bischin; Russell Dorer; David M Aboulafia
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-04-01

4.  Close but distinct regions of human herpesvirus 8 latency-associated nuclear antigen 1 are responsible for nuclear targeting and binding to human mitotic chromosomes.

Authors:  T Piolot; M Tramier; M Coppey; J C Nicolas; V Marechal
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma.

Authors:  Antonino Carbone; Annunziata Gloghini; Emanuela Vaccher; Michaela Cerri; Gianluca Gaidano; Riccardo Dalla-Favera; Umberto Tirelli
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

6.  Kaposi's Sarcoma-Associated Herpesvirus-Encoded circRNAs Are Expressed in Infected Tumor Tissues and Are Incorporated into Virions.

Authors:  Patrick S Moore; Yuan Chang; Bizunesh Abere; Jinghui Li; Hongzhao Zhou; Tuna Toptan
Journal:  mBio       Date:  2020-01-07       Impact factor: 7.867

7.  Multifocal cutaneous non-epitheliotropic B-cell lymphoma in a cat.

Authors:  Fausto Quintavalla; Rosanna Di Lecce; Daniele Carlini; Matteo Zanfabro; Anna M Cantoni
Journal:  JFMS Open Rep       Date:  2020-12-16

8.  Use of a multi-virus array for the study of human viral and retroviral pathogens: gene expression studies and ChIP-chip analysis.

Authors:  Elodie Ghedin; Anne Pumfery; Cynthia de la Fuente; Karen Yao; Naomi Miller; Vincent Lacoste; John Quackenbush; Steven Jacobson; Fatah Kashanchi
Journal:  Retrovirology       Date:  2004-05-25       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.